Sdelci Lab

Sdelci LabSdelci Lab

Gene Regulation, Stem Cells and Cancer

Sdelci Lab
The epigenetic face of cancer metabolism
Group leader

Sdelci Lab

The epigenetic face of cancer metabolism
Group leader

2005 B.Sc. in Biotechnology, University of Florence, Florence (Italy)
2007 M.Sc. in Medical Biotechnology, University of Florence, Florence (Italy)
2007-2009 Internship at the Department of Pathology and Oncology, University of Florence (Italy)
2012 PhD in Biomedicine, IRB (Institute for Research in Biomedicine), Barcelona
2013-2016 JDRF Postdoctoral fellow at CeMM (Research Center for Molecular Medicine of the Austrian Academy of Sciences), Vienna
2016-2018 Senior postdoctoral researcher at CeMM (Research Center for Molecular Medicine of the Austrian Academy of Sciences), Vienna
2017 M.Sc. in Bioethics, University Ramon Llull, Barcelona (Spain)
January 2019 Group Leader at the Centre for Genomic Regulation (CRG), Barcelona (Spain)

News

CRG scientists receive €5m to research cancer, ageing and evolution (03/09/2019)
Sara Sdelci, a Group Leader running a lab in the CRG’s gene regulation, stem cells and cancer research programme, is one of the recipients. Her project EPICAMENTE will explore the roles of enzymes in cancer proliferation.  

Summary

The central role of metabolic rewiring during cancer progression is undeniable, but its direct impact on chromatin functions has been poorly investigated. 

We recently described that enzymes of central metabolism can localize on chromatin in cancer cells. However, their chromatin-associated roles remain mostly elusive. Therefore, the scope of our research is to dissect the role of enzymatic activities on chromatin, with a particular focus on cancer. To do so, we apply chemical biology and functional genomics approaches to unbiased chromatin reporters (REDS) for selected metabolic enzymes. We aim to identify the molecular networks defining the direct interplay between chromatin and cancer metabolism. Our research focuses on a brand-new area of cancer biology and has the potential to uncover novel chromatin-associated metabolic vulnerabilities. The breakthrough aspect of our investigation has been recognized by the European Research Council which, in 2019, awarded us with one of the prestigious ERC starting grant (https://erc.europa.eu/projects-figures/erc-funded-projects/results?search_api_views_fulltext=epicamente).

 


Credit: Rito Ghose